The Indian government has capped trade margins at 30% of the Maximum Retail Price (MRP) for 110 non-scheduled anti-cancer drugs. This policy aims to save patients approximately ₹2,500 crore annually by curbing high markups that have reached up to 700%. While the rule focuses on distribution and pharmacy margins rather than manufacturing revenue, the 10-day implementation window poses operational challenges for the supply chain.
The Indian government has introduced a 30% cap on trade margins for non-scheduled anti-cancer medications. This move is designed to standardize pricing across retail pharmacies, hospitals, and online sales platforms, where high markups have previously inflated the cost of life-saving treatments. The directive applies to both branded and generic versions, including imported and domestic products.
Curbing Excessive Markups
Official investigations, including those by the National Pharmaceutical Pricing Authority, found that trade markups for these drugs frequently hover around 170%, with some instances as high as 700%. By capping these margins at 30% of the Maximum Retail Price, the government expects to reduce the final price for patients significantly, with an estimated annual saving of ₹2,500 crore. The Directorate General of Health Services is currently finalizing the list of 110 specific medicines covered under this regulation, a process expected to conclude within the next 10 days.
Impact on Supply Chain and Manufacturers
The new regulation focuses specifically on trade margins, which are the profits earned by distributors and retailers between the factory gate and the final sale to the patient. According to the government’s statement, the policy is structured to avoid hitting the primary revenues of pharmaceutical manufacturers. However, investors should monitor whether this adjustment creates pressure on pharmacy chains and distribution networks that rely on higher margins for operations.
This decision follows recent scrutiny by the Supreme Court regarding the wide price disparities in oncology drugs. It also builds on a 2019 pilot project, which applied a similar margin cap to 42 oncology drugs and reportedly saved patients nearly ₹1,000 crore annually.
Risks and Monitorables
While the goal is patient affordability, the short 10-day window for implementation may create immediate operational challenges for distributors and hospitals to align their pricing structures. There is also a risk that if regulated margins are perceived as too low, it could affect the distribution interest for certain lower-priced medications.
Moving forward, the primary monitorables for investors include the final list of drugs affected, the actual impact on the revenue of pharmacy chains and hospital-based medicine distribution, and whether the implementation proceeds smoothly without causing supply shortages. The sector will also need to adapt to this stricter pricing environment as the government continues its broader push to control costs in the oncology medicine market.